Leong Patrick K K, Devillez Angela, Sandberg Monica B, Yang Li E, Yip Daniel K P, Klein Jon B, McDonough Alicia A
Department of Physiology and Biophysics, University of Southern California Keck School of Medicine, Los Angeles 90089-9142, USA.
Am J Physiol Renal Physiol. 2006 Apr;290(4):F854-63. doi: 10.1152/ajprenal.00353.2005. Epub 2005 Nov 1.
Angiotensin-converting enzyme (ACE) inhibitors such as captopril, which block ANG II formation, are commonly used for treatment of hypertension. There is substantial evidence that the proximal tubule (PT) is a primary target site for captopril but the molecular mechanisms for its action in PT are not well defined. The aim of this study was to determine the physiological and molecular changes in PT provoked by acute captopril treatment in the absence of changes in blood pressure or glomerular filtration rate (GFR). Captopril (infused at 12 microg/min for 20 min) did not change blood pressure or GFR but induced an immediate (<10 min) increase in PT flow measured with a nonobstructive optical method (to 117 +/- 14% of baseline) along with a rapid diuresis from 2.1 +/- 0.6 mg/min (baseline) to 3.7 +/- 0.9 mg/min (captopril). Captopril also provoked a significant retraction of PT Na(+)/H(+) exchanger isoform 3 (NHE3), NHE regulatory factor (NHERF)-1, myosin-VI, and Na(+)-P(i) cotransporter type 2 (NaPi2), but not ACE, out of apical microvillus-enriched membranes. Proteomic analysis with MALDI-TOF MS revealed an additional eight abundant membrane-associated proteins that redistributed out of the microvillus-enriched membrane during captopril treatment: megalin, myosin II-A, clathrin, aminopeptidase N, DPPIV, ezrin, moesin, and vacuolar H(+)-ATPase subunit beta(2). In summary, captopril can rapidly depress PT reabsorption in the absence of a change in GFR or BP and provokes the redistribution of a set of transporters and transporter-associated proteins that likely participate in the decrease in PT reabsorption and may also contribute to the blood pressure-lowering effect of ACE inhibitors.
血管紧张素转换酶(ACE)抑制剂,如卡托普利,可阻断血管紧张素II的形成,常用于治疗高血压。有大量证据表明近端小管(PT)是卡托普利的主要作用靶点,但它在PT中的作用分子机制尚不清楚。本研究的目的是确定在血压或肾小球滤过率(GFR)无变化的情况下,急性卡托普利治疗引起的PT生理和分子变化。卡托普利(以12微克/分钟的速度输注20分钟)未改变血压或GFR,但通过非阻塞性光学方法测量发现,PT流量立即(<10分钟)增加(达到基线的117±14%),同时尿量迅速增加,从2.1±0.6毫克/分钟(基线)增至3.7±0.9毫克/分钟(卡托普利)。卡托普利还引起PT钠/氢交换体同工型3(NHE3)、NHE调节因子(NHERF)-1、肌球蛋白-VI和2型钠-磷酸共转运体(NaPi2)从顶端富含微绒毛的膜中显著回缩,但ACE没有。用基质辅助激光解吸电离飞行时间质谱(MALDI-TOF MS)进行的蛋白质组分析显示,在卡托普利治疗期间,另外有8种丰富的膜相关蛋白从富含微绒毛的膜中重新分布:巨蛋白、肌球蛋白II-A、网格蛋白、氨肽酶N、二肽基肽酶IV、埃兹蛋白、膜突蛋白和液泡H⁺-ATP酶亚基β2。总之,在GFR或血压无变化的情况下,卡托普利可迅速降低PT重吸收,并引起一组转运体和转运体相关蛋白的重新分布,这些蛋白可能参与了PT重吸收的减少,也可能有助于ACE抑制剂的降压作用。